Assort Health just closed a $50 million Series B round at a $750 million valuation, marking the latest surge in AI-powered healthcare automation. The startup's voice agents handle repetitive patient calls for specialty practices, joining a growing field of companies betting AI will transform medical office operations. Sources familiar with the deal confirm Lightspeed Venture Partners led the round.
Assort Health has become the latest healthcare AI startup to land massive funding, securing $50 million in a Series B round that values the company at $750 million according to three sources familiar with the deal speaking to TechCrunch. The round, led by Lightspeed Venture Partners, comes just four months after the company's $22 million Series A, highlighting the breakneck pace of investment in AI-powered medical office automation.
The timing couldn't be more telling. Healthcare investors are placing increasingly large bets that AI voice agents will revolutionize how medical practices handle the endless stream of patient calls that bog down front desk staff. "The company's AI voice agents are designed to take over high-volume, repetitive tasks like scheduling, cancellations, and frequently asked questions," according to the TechCrunch exclusive, allowing human staff to focus on more complex patient interactions.
Assort Health finds itself riding a wave of similar funding announcements. Just last week, EliseAI announced a massive $250 million Series E led by Andreessen Horowitz, valuing the real estate and healthcare automation company at $2.2 billion. Meanwhile, Hello Patient quietly raised a $20 million Series A at a $100 million valuation from Scale Venture Partners earlier this month, according to sources.
The surge reflects a broader transformation sweeping healthcare. Medical practices have already embraced AI scribes from companies like Abridge and Ambience Healthcare to reduce documentation burdens. Now investors are betting patient communication represents the next frontier for AI implementation, particularly as specialty practices struggle with long wait times and patient retention.
For Assort Health, the market opportunity appears substantial. The startup serves small and medium specialty care offices where "fast responses by an AI agent may help these offices lose fewer patients to competing practices," as the company positions itself against traditional appointment booking systems. With annual recurring revenue hovering just above $3 million, the company is "growing quickly," according to two sources familiar with the business.
The company's expansion strategy reveals its ambitions. Initially focused on orthopedic and physical therapy offices, Assort Health has recently branched into obstetrics-gynecology, dermatology, and dentistry. This specialty-specific approach mirrors successful healthcare software companies that build deep domain expertise rather than pursuing one-size-fits-all solutions.
Founded just two years ago by Jon Wang, a former medical student who "traded his path in medicine for the world of startups," and Jeff Liu, a former Meta engineer, Assort Health represents the latest example of healthcare insiders turning their industry knowledge into venture-backed businesses. Wang's medical background provides crucial credibility when selling to healthcare practices notoriously resistant to new technology.
The funding environment for healthcare AI remains robust despite broader venture capital tightening. The combination of proven demand for medical office automation, regulatory tailwinds supporting AI adoption in healthcare, and the clear ROI of reducing administrative overhead continues attracting major investors. Lightspeed's decision to lead speaks to the firm's conviction that voice AI will become standard infrastructure for medical practices.
What's particularly striking about this funding round is the compressed timeline. Moving from Series A to Series B in four months suggests either exceptional growth metrics or fierce competition for the deal. Given the competitive landscape with EliseAI's billion-dollar-plus valuation and Hello Patient's recent raise, investors appear eager to secure positions in what they view as a winner-take-most market.
Assort Health's rapid-fire funding progression from Series A to Series B in four months signals that healthcare AI automation has moved from experimental to essential. As specialty practices face mounting pressure to improve patient experience while controlling costs, AI voice agents are becoming the obvious solution. The question isn't whether this technology will reshape medical office operations, but which companies will capture the largest share of a market that investors clearly believe is worth billions.
